Roche to advance prasinezumab into Phase III development for early-stage Parkinson’s disease
Results from Phase IIb PADOVA and longer term follow-up data suggest clinical…
EHA 2025 | Multiple Studies Report Encouraging Data of Olverembatinib in Ph+ ALL
ROCKVILLE, Md. and SUZHOU, China, June 15, 2025 (GLOBE NEWSWIRE) -- Ascentage…
Positive Late-Breaking Data for Incytes First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia Presented at EHA2025
Data demonstrates the potential for INCA033989 to modify disease by directly inhibiting…
Connect Biopharma Presents Data Supporting Rademikibart at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress
– Rademikibart significantly improved lung function and asthma control in patients with…
ESOC 2025: Combined oral contraceptives triple risk of cryptogenic stroke in young women, new study shows
HELSINKI, May 20, 2025 /PRNewswire/ -- New research presented today at the…
TrialWire the AI and Algorithm-powered Platform Named a Fierce CRO Award Finalist in the Outstanding Patient Recruitment and Retention Category
SAN FRANCISCO, May 20, 2025 (GLOBE NEWSWIRE) -- TrialWire today announces it…
Coave Therapeutics Launches coAAV-CSF-01, a Novel CNS-Targeted Gene Therapy Vector for Neurodegenerative and other CNS Diseases
New breakthrough data from studies with Coave’s ALIGATER™-engineered AAV2-based capsid coAAV-CSF-01 (S01coAAV2)…
Bio-Path Holdings Achieves Third Pre-Clinical Milestone Confirming Potential of BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients
Data suggest BP1001-A prevents fatty acid-induced insulin resistance in cells May 01,…
Spanios and White Lion Capital LLC Announce Strategic Partnership to Accelerate Drug Development
HOUSTON, April 25, 2025 (GLOBE NEWSWIRE) -- Spanios, a leader in human-derived…
International Olympic Case Study Competition celebrates record participation and outstanding winning teams
08 April 2025 - Over the past year, 375 undergraduate and master’s…
